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FEN1 has key roles in Okazaki fragmentmaturation during replication, long patch base exci-
sion repair, rescue of stalled replication forks, maintenance of telomere stability and
apoptosis. FEN1 may be dysregulated in breast and ovarian cancers and have clinicopatho-
logical significance in patients. We comprehensively investigated FEN1 mRNA expression
in multiple cohorts of breast cancer [training set (128), test set (249), external validation
(1952)]. FEN1 protein expressionwas evaluated in 568 oestrogen receptor (ER) negative breast
cancers, 894 ER positive breast cancers and 156 ovarian epithelial cancers. FEN1mRNA over-
expressionwashighly significantly associatedwithhighgrade ( p¼4.891057), highmitotic
index ( p ¼ 5.25  1028), pleomorphism ( p ¼ 6.31  1019), ER negative ( p ¼ 9.02  1035), PR
negative ( p ¼ 9.24  1024), triple negative phenotype ( p ¼ 6.67  1021), PAM50.Her2
( p¼ 5.19 1013), PAM50. Basal ( p¼ 2.7 1041), PAM50.LumB ( p¼ 1.56 1026), integrative
molecular cluster 1 (intClust.1) ( p ¼ 7.47  1012), intClust.5 ( p ¼ 4.05  1012) and intClust.
10 ( p ¼ 7.59  1038) breast cancers. FEN1 mRNA overexpression is associated with poor
breast cancer specific survival in univariate ( p ¼ 4.4  1016) and multivariate analysiscology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham,
m NG51PB, U.K. Tel.: þ44 (0) 115 823 1850; fax: þ44 (0) 115 823 1849.
nottingham.ac.uk (S. Madhusudan).
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M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 3 2 6e1 3 3 8 1327( p ¼ 9.19  107). At the protein level, in ER positive tumours, FEN1 overexpression remains
significantly linked to high grade, high mitotic index and pleomorphism (ps < 0.01). In ER
negative tumours, high FEN1 is significantly associated with pleomorphism, tumour type,
lymphovascular invasion, triple negative phenotype, EGFR and HER2 expression
(ps < 0.05). In ER positive as well as in ER negative tumours, FEN1 protein overexpression is
associated with poor survival in univariate and multivariate analysis (ps < 0.01). In ovarian
epithelial cancers, similarly, FEN1 overexpression is associated with high grade, high stage
and poor survival (ps < 0.05). We conclude that FEN1 is a promising biomarker in breast
and ovarian epithelial cancer.
ª 2014 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.1. Introduction FEN1 has been reported (Singh et al., 2008). In a small cohortThe flap structure specific endonuclease (FEN1) is critical for
processing DNA intermediates generated during DNA long
patch base excision repair (LP-BER) and Okazaki fragment
maturation during replication. FEN1 is also essential for
rescue of stalled replication forks, maintenance of telomere
stability and apoptotic fragmentation of DNA (Shen et al.,
2005; Zheng et al., 2011). FEN1 belongs to XPG/RAD2 endonu-
clease family and FEN1 gene is located at 11q22. FEN1 pos-
sesses flap endonuclease, 50 exonuclease and gap-
endonuclease activities to accomplish its various biological
functions. FEN1 is subjected to post-translational modifica-
tions such as acetylation, phosphorylation, sumoylation,
methylation and ubiquitylation that regulate nuclease activ-
ities as well as proteineprotein interactions and sub-cellular
compartmentalization (Shen et al., 2005; Zheng et al., 2011).
FEN1may have a role in carcinogenesis. A tumour suppres-
sor function for FEN1 has been shown in preclinical models
(Henneke et al., 2003a, 2003b; Kucherlapati et al., 2007;
Kucherlapati et al., 2002; Wu et al., 2012; Xu et al., 2011).
Whereas, FEN1 homologous knock out in mice is embryoni-
cally lethal FEN1 heterozygous mice are viable (Larsen et al.,
2003). A double heterozygous mouse model with a mutation
in FEN1 and adenomatous polyposis coli (APC) gene displayed
enhanced cancer development and poor survival
(Kucherlapati et al., 2007). In addition, a FEN1 E160D mutant
mouse model displayed altered DNA repair as well as
apoptotic DNA fragmentation and associated with increased
mutation frequency and cancer development (Larsen et al.,
2008; Zheng et al., 2007). In human studies, polymorphic var-
iants of FEN1 may be associated with increased cancer sus-
ceptibility (Liu et al., 2012; Yang et al., 2009). In established
tumours, preclinical evidence suggests that FEN1 over expres-
sionmay promote cancer progression and survival (Kim, 1998;
Kim et al., 2005; Krause et al., 2005; Sato et al., 2003). Prolifer-
ating cells consistently over express FEN1 compared to quies-
cent cells (Kim, 1998). In pro-myelocytic leukemia cells (HL-
60), FEN1 gene expression was shown to be higher during
mitotic phase compared to the resting phase of the cell cycle
and FEN1 expression markedly decreased upon induction of
terminal differentiation in cells (Kim, 1998). FEN1 mRNA
over expression has also been demonstrated in lung cancer
cell lines (Sato et al., 2003) and gastric cancer cell lines (Kim
et al., 2005). In human tumours, frequent overexpression ofof 50 breast tumours, FEN1was shown to be upregulated in tu-
mours compared to normal tissue in that study (Singh et al.,
2008). However, clinicopathological significance of FEN1 upre-
gulation remains unknown in breast and ovarian cancer
(Singh et al., 2008).
We hypothesised that FEN1may be dysregulated in human
breast and ovarian cancer, contributing to the aetiology of the
disease. We investigated FEN1 mRNA as well as FEN1 protein
expression in large cohorts of breast and ovarian tumours
and correlated to clinicopathological variables and outcome
data. In the current study we demonstrate that FEN1 overex-
pression is associated with aggressive phenotype and poor
survival in breast and ovarian cancer. The data provides evi-
dence that FEN1 is a promising biomarker.2. Materials and methods
2.1. FEN1 gene expression (training set)
The study population used was derived from the Nottingham
Tenovus Primary Breast Carcinoma Series of women aged 70
years or less, who presented with stage I and II primary oper-
able invasive breast carcinomas. The patient demographics
for the training set are summarized in supplementary Table
1 of supporting information. Gene expression profiling has
been previously described (Chin et al., 2007). Briefly, total
RNA was extracted from a series of frozen breast cancers
retrieved from Nottingham Hospitals NHS Trust Tumour
Bank between 1986 and 1992. RNA integrity and DNA
contamination were analysed using Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA). Total RNA was
biotin-labelled using the Illumina TotalPrep RNA Amplifica-
tion kit (Ambion, Austin, TX, USA) according to manufac-
turer’s instructions. Biotin-labelled cRNA (1.5 mg) was used
for each hybridisation on Sentrix Human-6 BeadChips (Illu-
mina, San Diego, CA, USA) in accordance with the manufac-
turer’s protocol. Illumina gene expression data containing
47,293 transcripts were analysed and summarised in the Illu-
mina Bead Studio software. Analyses of the probe level data
were done using the beadarray Bioconductor package. The
expression data are available at the EBI website (http://
www.ebi.ac.uk/miamexpress/) with the accession number
E-TABM-576.
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The Uppsala cohort originally composed of 315 women repre-
senting 65% of all breast cancers resected in Uppsala County,
Sweden, from January 1, 1987, to December 31, 1989. Demo-
graphics are summarized in Supplementary Table S2 of
supporting information and also described elsewhere (Bergh
et al., 1995). Tumour samples were microarray profiled on
the Affymetrix U133A&B genechips. Microarray analysis was
carried out at the Genome Institute of Singapore. All microar-
ray data are accessible at National Center for Biotechnology
Information (NCBI) Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/). Data can be accessed via series
accession number (GSE4922). RNA preparation, microarray
hybridization, and data processing were carried out essen-
tially as described (Pawitan et al., 2005). All data were normal-
ized using the global mean method (MAS5), and probe set
signal intensities were natural log transformed and scaled
by adjusting the mean signal to a target value of log 500.2.3. FEN1 gene expression (external validation)
External validation was performed in the METABRIC (Molecu-
lar Taxonomy of Breast Cancer International Consortium)
cohort. The METABRIC study protocol, detailing themolecular
profiling methodology in a cohort of 1980 breast cancer sam-
ples is described by (Curtis et al. 2012). Patient demographics
are summarized in supplementary Table S3 of supporting
information. ER positive and/or lymphnode negative patients
did not receive adjuvant chemotherapy. ER negative and/or
lymphnode positive patients received adjuvant chemo-
therapy. RNA was extracted from fresh frozen tumours and
subjected to transcriptional profiling on the Illumina HT-12
v3 platform. The data was pre-processed and normalized as
described previously (Curtis et al. 2012). FEN1 expression
was investigated in this data set. The Chi-square test was
used for testing association between categorical variables
and a multivariate Cox model was fitted to the data using as
endpoint breast cancer specific death. Recursive partitioning
(Hothorn et al., 2006) was used to identify a cut-off in gene
expression values such that the resulting subgroups have
significantly different survival courses.2.4. FEN1 protein expression in breast cancer
The study was performed in a consecutive series of 1650 pa-
tients with primary invasive breast carcinomas who were
diagnosed between 1986 and 1999 and entered into the Not-
tingham Tenovus Primary Breast Carcinoma series. All pa-
tients were treated uniformly in a single institution and
have been investigated in a wide range of biomarker studies
(Abdel-Fatah et al., 2013b, 2013c, 2014a, 2014b; Sultana et al.,
2013). Clinicopathological characteristics of ER negative
cohort is summarized in Supplementary Table S6 of
supporting information. Patient demographics for ER positive
cohort are summarized in Supplementary Table S7 of
supporting information. Supplemental treatment data 1 sum-
marizes various adjuvant treatments received by patients in
Nottingham Tenovus Primary Breast Carcinoma series.2.5. FEN1 protein expression in ovarian epithelial cancer
Investigation of the expression of FEN1 in ovarian epithelial
cancer was carried out on a tissue microarray of 195 consecu-
tive ovarian epithelial cancer cases treated at Nottingham
University Hospitals (NUH) between 2000 and 2007. Patients
were comprehensively staged as per International Federation
of Obstetricians and Gynaecologists (FIGO) Staging System for
Ovarian Cancer. Survival was calculated from the operation
date until 1st of October 2012 when any remaining survivors
were censored. Patient demographics are summarised in
summarized in Supplementary Table S11 of supporting
information. Platinum resistance was defined as patients
who had progression during first-line platinum chemotherapy
or relapse within 6 months after treatment. Construction of
TMAs and immunohistochemical protocols were similar to
those described for breast cancer TMAs previously.
2.6. Tissue microarrays (TMAs) and
immunohistochemistry (IHC)
Tumours were arrayed in tissue microarrays (TMAs) con-
structedwith 2 replicate 0.6 mm cores from the centre and pe-
riphery of the tumours. The TMAs were immuno
histochemically profiled for FEN1 and other biological anti-
bodies (Supplementary Table S8 of supporting information)
as previously described (Abdel-Fatah et al., 2013b, 2013c,
2014a, 2014b; Sultana et al., 2013). Immunohistochemical
staining for FEN1 was performed using the Leica Bond Refine
Detection kit according to manufacturer instructions (Leica
Microsystems). Pre-treatment of TMA sections was performed
with citrate buffer (pH 6.0) antigen for 20 min and heated
further for 20 min in a microwave. TMA sections were then
incubated for 15 min at room temperature with 1:200 anti-
FEN1 rabbit polyclonal antibody (NBP1-67924, Novus Biologi-
cals, Littleton, CO, USA). Also, positive and negative (by omis-
sion of the primary antibody and IgG-matched serum)
controls were prepared for each set of samples. To validate
the use of TMAs for immunophenotyping, full-face sections
of 40 cases were stained and protein expression levels of the
different antibodies were compared. The concordance be-
tween TMAs and full-face sectionswas excellent (k¼ 0.8). Pos-
itive and negative (by omission of the primary antibody and
IgG-matched serum) controls were included in each run.
2.7. Evaluation of immune staining
The tumour cores were evaluated by specialist pathologist
blinded to the clinicopathological characteristics of patients.
Whole field inspection of the core was scored and intensities
of nuclear aswell as cytoplasmic stainingwere grouped as fol-
lows: 0 ¼ no staining, 1 ¼ weak staining, 2 ¼moderate stain-
ing, 3 ¼ strong staining. The percentage of each category
was estimated (0e100%). H-score (range 0e300) was calculated
bymultiplying intensity of staining and percentage staining as
previously described (Abdel-Fatah et al., 2013b, 2013c, 2014a,
2014b; Sultana et al., 2013). Low/negative FEN1 (FEN1-) expres-
sion was defined by mean of H-score of 100. Not all cores
within the TMA were suitable for IHC analysis due to missing
cores or absence of tumour cells.
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ommended by McShane et al. (2005), were followed
throughout this study. This work was approved by Notting-
ham Research Ethics Committee.
2.8. Statistical analysis
Data analysiswas performed using SPSS (SPSS, version 17 Chi-
cago, IL). Where appropriate, Pearson’s Chi-square, Fisher’s
exact, Student’s t and ANOVA one way tests were used. Cu-
mulative survival probabilities were estimated using the
KaplaneMeier method, and differences between survival
rates were tested for significance using the log-rank test.
Multivariate analysis for survival was performed using the
Cox proportional hazard model. The proportional hazards
assumption was tested using standard logelog plots. Hazard
ratios (HR) and 95% confidence intervals (95% CI) were esti-
mated for each variable. All tests were two-sided with a 95%
CI and a p value <0.05 considered significant. For multiple
comparisons, p values were adjusted according to Holm-
Bonferroni correction method.
2.9. Cell lines and culture
To evaluate the specificity of the FEN1 antibody used in the
current study FEN1 deficient and proficient cells were investi-
gated. FEN1 deficient HeLa SilenciX cells and control FEN1
proficient HeLa SilenciX cells were purchased from Tebu-
Bio (www.tebu-bio.com). SilenciX cells were grown in DMEM
medium (with L-Glutamine 580 mg/L, 4500 mg/L D19 Glucose,
with 110 mg/L Sodium Pyruvate) supplemented with 10% FBS,
1% penicillin/streptomycin and 125 mg/ml Hygromycin B.
Western blot analysis was performed as described previously
(Sultana et al., 2013).3. Results
3.1. High FEN1 transcript levels correlate to aggressive
biology and adversely impact breast cancer clinical outcomes
We evaluated FEN1 mRNA expression in multiple cohorts of
breast cancer (training set, test set and external validation
cohort). Clinicopathological characteristics are summarized
in Supplementary Tables S1, S2 and S3. In the training set
(n ¼ 128), 40.6% of tumours had high FEN1 mRNA expression,
which was significantly associated with high grade
( p < 0.0001), high mitotic index ( p < 0.0001), pleomorphism
( p < 0.0001), glandular de-differentiation ( p ¼ 0.032), HER2
overexpression ( p ¼ 0.003), oestrogen receptor (ER) negative
( p ¼ 0.001), progesterone receptor (PgR) negative ( p ¼ 0.005)
and triple negative phenotype ( p ¼ 0.001) (Supplementary
Table S4). High FEN1 mRNA expression in tumours was also
associated with adverse disease specific survival in patients
( p ¼ 0.008) (Figure 1a). In the test set (n ¼ 249), 50.2% of tu-
mours had high FEN1 mRNA expression, which remained
associated with high T-stage ( p ¼ 0.007), lymph node positiv-
ity ( p ¼ 0.012), high grade ( p < 0.0001), high molecular grade
( p < 0.0001), mutant p53 ( p < 0.0001) and ER negativity
( p ¼ 0.001) (Supplementary Table S5). High FEN1 mRNAexpression in tumours was associated with adverse disease
specific survival in patients ( p ¼ 0.00009) (Figure 1b).
External validation was conducted in a large series of 1952
tumours comprising the METABRIC (Molecular Taxonomy of
Breast Cancer International Consortium) cohort. 52.25%
(1020/1952) of tumours had high FEN1 mRNA expression,
which was significantly associated with aggressive clinico-
pathological features (Table 1), including high histological
grade ( p < 0.0001), high mitotic index ( p < 0.0001), pleomor-
phism ( p < 0.0001), glandular de-differentiation ( p ¼ 0.006),
HER2 overexpression ( p< 0.0001), absence of hormonal recep-
tors (ER-/PgR-) ( p < 0.0001), lymph node positivity (0.02), pres-
ence of basal like phenotypes ( p < 0.0001) and triple negative
phenotypes ( p < 0.0001). High FEN1 mRNA expression was
also found to be significantly associated with previously
describedmolecular phenotypes in breast cancer: PAM50.Her2
( p < 0.0001), PAM50. Basal ( p < 0.0001) and PAM50.LumB
( p < 0.0001) breast tumours. However, PAM50.LumA tumours
were more likely to express low levels of FEN1 mRNA
( p < 0.0001).
The METABRIC study by joint clustering of copy number
and gene expression data has identified 10 novel biological
subgroups [labelled integrative clusters (intClust) 1e10] with
good, intermediate or poor prognosis (Curtis et al.). We inves-
tigated whether FEN1mRNA expression would associate with
these distinct biological subgroups. High FEN1 mRNA expres-
sion was significantly associated with intClust.1 ( p < 0.0001),
intClust.5 ( p < 0.0001), intClust.9 ( p < 0.0001) and intClust.10
( p < 0.0001), which had the worst clinical outcome in the
METABRIC study (Curtis et al.). Low FEN1 mRNA expression
was associated with intClust.3 ( p < 0.0001), intClust.4
( p < 0.0001), intClust.7 ( p ¼ 0.003) and intClust.8
( p < 0.0001), which had intermediate to good prognosis in
the METABRIC study (Curtis et al.). High FEN1 mRNA expres-
sion in tumours was associated with adverse disease specific
survival in the whole cohort ( p < 0.0001) (Figure 1c). In multi-
variate Cox regression analysis that included other validated
prognostic factors, such as lymph node stage, histological
grade and tumour size (NPI components), FEN1mRNA expres-
sion was a powerful independent predictor for clinical
outcome ( p < 0.0001) (Table 2). Moreover, in patients who
received adjuvant endocrine therapy (n ¼ 1199), high FEN1
mRNA expression remained significantly associated with
adverse disease specific survival ( p< 0.0001) (Figure 1d). In pa-
tients who received adjuvant chemotherapy (n ¼ 413), high
FEN1 mRNA expression was likewise associated with adverse
disease specific survival ( p ¼ 0.019) (Figure 1e).
FEN1mRNA expression analysis in the training set, test set
and in the external validation cohort provides confirmatory
evidence that high FEN1 mRNA expression is associated with
adverse clinicopathological features, aggressive molecular
phenotypes and poor survival in patients.
3.2. FEN1 protein expression is linked to aggressive
breast cancer and poor survival
As the multifunctional roles of FEN1 are likely regulated by
several mechanisms, including sub-cellular compartmentali-
zation between, for example, the nucleus and cytoplasm/
mitochondria, we proceeded to evaluate FEN1 protein
Figure 1 e FEN1 gene expression in breast cancer. Kaplan Meier curves showing breast cancer specific survival in the (a) training set, (b) test set,
(c) external validation (METABRIC) cohort, (d) METABRIC cohort patients receiving endocrine therapy, and (e) METABRIC cohort patients
receiving chemotherapy.
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tumours and 894 ER positive breast tumours. Clinicopatholog-
ical characteristics are summarized in Supplementary Tables
S6 and S7. Treatment data is summarized in supplementary
treatment data 1. We also correlated FEN1 protein expression
to other biomarkers of aggressive phenotype (ER, PR, EGFR,
CK14, CK5/6, CK17, CK18, HER2) and DNA repair (PARP1,
BRCA1, ATM, XRCC1 and TOP2A). Antigens, primary anti-
bodies, clone, source, optimal dilution and scoring system
for each immunohistochemical marker are summarized in
supplementary Table S8.
We first confirmed the specificity of FEN1 antibody used in
the current study. As shown in Figure 2a1, FEN1 proficient cell
line shows robust FEN1 protein expression whereas FEN1
knockdown cell shows almost complete absence of FEN1 pro-
tein expression. We then conducted immunohistochemical
investigations. In 568 ER negative tumours (Figure 2a2), we
found significant associations between FEN1 expression and
pleomorphism ( p ¼ 0.012), tumour type ( p < 0.0001), lympho-
vascular invasion ( p ¼ 0.007), progesterone receptor
( p < 0.0001), EGFR overexpression ( p ¼ 0.04), HER2 overex-
pression ( p ¼ 0.029) and triple negative phenotype
( p ¼ 0.032). FEN1 expression was also significantly associated
with expression of other DNA repair factors, including BRCA1
( p < 0.0001), PARP1 ( p < 0.0001), XRCC1 ( p < 0.0001) andTOP2A ( p < 0.0001) (full data is summarized in
supplementary Table S9). High nuclear/high cytoplasmic
FEN1 expression was associated with poor survival
( p ¼ 0.003) (Figure 2b). In patients with early stage lymph
node negative (low risk) tumourswho did not receive adjuvant
chemotherapy, high nuclear/high cytoplasmic tumours
remained significantly associated with poor survival
( p ¼ 0.009) (Figure 2c). In patients who received CMF (cyclo-
phosphamide, methotrexate and 5-Fluoruracil) chemo-
therapy, high nuclear/high cytoplasmic was associated with
poor survival ( p ¼ 0.05) (Figure 2d). The group that received
anthracycline adjuvant chemotherapy did not reach signifi-
cance ( p¼ 0.211), although there was a trend toward poor sur-
vival in high nuclear/low cytoplasmic tumours
(Supplementary Figure S1a). In the multivariate COX model,
FEN1 expression is independently associated with breast can-
cer specific survival ( p ¼ 0.007), as well as progression free
survival ( p ¼ 0.003) (Table 3).
In 894 ER positive breast tumours, we similarly found sig-
nificant association between FEN1 expression and tumour
size ( p ¼ 0.004), grade ( p < 0.0001), pleomorphism
( p ¼ 0.0004), tumour type ( p < 0.0001), tubule formation
( p < 0.0001) and lymphovascular invasion ( p ¼ 0.007). FEN1
expression was also associated with other DNA repair factors,
such as BRCA1 ( p ¼ 0.003), XRCC1 ( p < 0.0001), ATM
Table 1 e Association between FEN1 mRNA expression and clinico-pathologic variables.
Variable FEN1 mRNA expression X2 Adjusted p value
Low High
N ¼ 932 (47.75%) N ¼ 1020 (52.25%)
A) Pathological parameters
Tumour Size
T1 a þ b (1.0) 5 (0.26%) 3 (0.15%) 0.629
T1 c (>1.0e2.0) 1 (0.05%) 2 (0.1%) 0.938
T2 (>2.0e5) 10 (0.51%) 4 (0.2%) 0.131
T3 (>5) 909 (46.57%) 999 (51.18%) 0.649
Lymph node stage
Negative 520 (26.64%) 492 (25.2%) 0.000991
Positive (1-3 nodes) 225 (11.53%) 281 (14.4%) 0.0961
Positive (>3 nodes) 184 (9.43%) 244 (12.5%) 0.0297
Grade*
G1 136 (6.97%) 28 (1.43%) 9.38 3 1021
G2 471 (24.13%) 293 (15.01%) 9.64 3 1023
G3 278 (14.24%) 673 (34.48%) 4.89 3 1057
Tumour types
IDC-NST 11 (0.56%) 6 (0.31%) 0.245
Tubular 24 (1.23%) 2 (0.1%) 1.18 3 105
ILC 2 (0.1%) 2 (0.1%) 0.681
Medullary 2 (0.1%) 23 (1.18%) 0.000143
Others 754 (38.63%) 818 (41.91%) 0.737
Mitotic index
M1 (low; mitoses < 10) 591 (30.28%) 410 (21%) 1.89 3 1024
M2 (medium; mitoses 10e18) 158 (8.09%) 220 (11.27%) 0.0117
M3 (high; mitosis >18) 40 (2.05%) 216 (11.07%) 5.25 3 1028
Pleomorphism
1 (small-regular uniform) 12 (0.61%) 5 (0.26%) 0.099
2 (Moderate variation) 388 (19.88%) 208 (10.66%) 4.15 3 1024
3 (Marked variation) 390 (19.98%) 633 (32.43%) 6.31 3 1019
Tubule formation
1 (>75% of definite tubule) 51 (2.61%) 6 (0.31%) 3.69 3 1010
2 (10%e75% definite tubule) 243 (12.45%) 111 (5.69%) 5.55 3 1018
3 (<10% definite tubule) 496 (25.41%) 729 (37.35%) 1.19 3 1016
Molecular phenotypes
Her2 overexpression (No) 864 (44.26%) 846 (43.34%) 9.88 3 1011
(Yes) 68 (3.48%) 174 (8.91%) 9.88 3 1011
Triple negative (No) 859 (44.01%) 780 (39.96%) 6.67 3 1021
(Yes) 73 (3.74%) 240 (12.3%) 6.67 3 1021
Basal like (No) 900 (46.11%) 918 (47.03%) 1.69 3 108
(Yes) 32 (1.64%) 102 (5.23%) 1.69 3 108
ER (Negative) 95 (4.87%) 342 (17.52%) 9.02 3 1035
(Positive) 818 (41.91%) 667 (34.17%) 1.03 3 1030
PgR (Negative) 329 (16.85%) 593 (30.38%) 9.24 3 1024
(Positive) 603 (30.89%) 427 (21.88%) 9.24 3 1024
PAM50.Her2 61 (3.12%) 177 (9.07%) 5.19 3 1013
PAM50.Basal 43 (2.2%) 279 (14.29%) 2.7 3 1041
PAM50.LumA 548 (28.07%) 166 (8.5%) 3.78 3 1084
PAM50.LumB 129 (6.61%) 355 (18.19%) 1.56 3 1026
intClust.1 27 (1.38%) 112 (5.74%) 7.47 3 1012
intClust.2 29 (1.49%) 42 (2.15%) 0.287
intClust.3 217 (11.12%) 70 (3.59%) 2.74 3 1024
intClust.4 227 (11.63%) 104 (5.33%) 1.37 3 1016
intClust.5 43 (2.2%) 142 (7.27%) 4.05 3 1012
intClust.6 42 (2.15%) 43 (2.2%) 0.839
intClust.7 110 (5.64%) 79 (4.05%) 0.00316
intClust.8 185 (9.48%) 110 (5.64%) 3.35 3 108
intClust.9 36 (1.84%) 110 (5.64%) 1.06 3 108
intClust.10 16 (0.82%) 208 (10.66%) 7.59 3 1038
Bold ¼ Statistically significant.
* grade as defined by NGS; BRCA1: Breast cancer 1, early onset; HER2: human epidermal growth factor receptor 2; ER: oestrogen receptor;
PgR: progesterone receptor; CK: cytokeratin; Basal-like: ER-, HER2 and positive expression of either CK5/6, CK14 or EGFR; Triple negative:
ER-/PgR-/HER2-.
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Table 2 eMultivariate analysis using Cox regression analysis in the
METABRIC cohort confirms that FEN1 mRNA over expression is
a powerful independent prognostic factor.
Variable BCSS OS
HR p HR p
FEN1 mRNA
over expression
1.25 9.19 3 10L7 1.14 4.39 3 104
Tumour size 1.01 3.59 3 107 1.01 2.28 3 108
Grade 0.01 0.08
G1 1.0 1.0
G2 1.64 1.23
G3 1.90 1.31
Lymph node 1.46 3 104 2.01 3 103
Negative 1.0 1.0
Positive (1e3 nodes) 1.57 1.30
Positive (>3 nodes) 3.30 2.31
Bold ¼ Statistically significant.
BCSS; Breast cancer specific survival, OS; overall survival, HR; haz-
ard ratio, CI; confident interval.
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in Supplementary Table S10). High cytoplasmic/low nuclear
FEN1 tumours were associated with poor survival
( p ¼ 0.00016) in ER positive tumours (Figure 2e). In patients
with early stage lymph node negative (low risk) tumours
who did not receive adjuvant tamoxifen, high cytoplasmic/
low nuclear FEN1 tumours remained significantly associated
with poor survival ( p ¼ 0.003) (Supplementary Figure S1b). In
patients with high risk tumours who did not receive adjuvant
tamoxifen, high cytoplasmic/low nuclear FEN1 is associated
with poor survival ( p ¼ 0.026) (Figure 2f). On the other hand,
patients with tumours that had low cytoplasmic/low nuclear
FEN1 had better survival implying that these tumours could
be spared long term adjuvant endocrine therapy. In patients
with high risk tumours who received adjuvant tamoxifen,
high cytoplasmic/low nuclear FEN1 was associated with
poor survival ( p ¼ 0.003) (Figure 2g). On the other hand, pa-
tients with tumours that had high cytoplasmic/high nuclear
FEN1 had better survival implying that FEN1 could be predic-
tive biomarker of response to endocrine therapy. In the multi-
variate COX model, FEN1 expression was independently
associated with breast cancer specific survival ( p ¼ 0.003), as
well as progression free survival ( p ¼ 0.004) (Table 3).
Taken together, the FEN1mRNA expression as well as FEN1
protein expression data provides compelling evidence that
FEN1 expression is a prognostic and a predictive biomarker
in breast cancer.3.3. FEN1 protein expression is linked to aggressive
epithelial ovarian cancer and poor survival
We then proceeded to investigate the significance of FEN1 pro-
tein expression in 156 ovarian epithelial cancers. Demo-
graphics are summarized in Supplementary Table S11.
Positive nuclear expression of FEN1 was seen in 71/156
(45.5%) tumours, and 85/156 (54.5%) tumours were negative
for FEN1 protein expression (Figure 3a). FEN1 nuclear expres-
sion was associated with serous cystadenocarcinomas( p ¼ 0.05), higher pathological grade ( p ¼ 0.009), higher FIGO
stage ( p ¼ 0.046) and larger residual tumour burden following
surgery ( p¼ 0.034) (full data is summarized in Supplementary
Tables S12). Positive cytoplasmic expression of FEN1 was seen
in 126/156 (80.8%) tumours and 30/156 (19.2%) tumours were
negative for FEN1 cytoplasmic expression. FEN1 cytoplasmic
expression was significantly associated with serous cystade-
nocarcinomas ( p < 0.0001), more likely to be sub-optimally
debulked ( p ¼ 0.002), higher FIGO stage ( p ¼ 0.025) and larger
residual tumour burden following surgery ( p¼ 0.005) (full data
is summarized in supplementary Tables S13). Investigating
nuclear as well cytoplasmic expression together, we found
that high cytoplasmic/high nuclear FEN1 tumours had the
worst ovarian cancer specific ( p ¼ 0.006) (Figure 3b) and dis-
ease free ( p¼ 0.008) (Figure 3c). Evaluating nuclear expression
alone or cytoplasmic expression alone, FEN1 over expression
remains associated with poor survival in ovarian epithelial
cancers (Figures 3d, 3e, Supplementary figures S1c,d). In the
multivariate COX model, patients with FEN1 nuclear expres-
sion showed 2-fold increase in risk of death ( p ¼ 0.018)
(Supplementary Table S14). The multivariate Cox model was
adjusted for CA-125 response, FIGO stage and tumour grade.
Taken together, the data provides evidence that FEN1 over-
expression is a promising biomarker in ovarian epithelial
cancers.4. Discussions
This is the largest and the first comprehensive study to eval-
uate FEN1 in breast and ovarian cancers. In breast cancer,
high FEN1 mRNA is linked to aggressive features such as
high grade, high mitotic index, pleomorphism, de-
differentiation, PAM50. Her2 and PAM50. Basalmolecular phe-
notypes. FEN1 is essential for the repair of oxidative base dam-
age through long-patch base excision repair. The data
presented here suggests that high FEN1 mRNA expression is
an adaptive response to oxidative stress that is common in
breast cancer cells (Brown and Bicknell, 2001). Although not
fully understood, a recent study suggested FEN1 promoter
hypomethylation as a mechanism for FEN1 mRNA over
expression in tumours (Singh et al., 2008). High FEN1 mRNA
seen in tumours with high mitotic index also concurs with
previous studies demonstrating FEN1 upregulation in cycling
cells (Kim, 1998; Kim et al., 2005; Krause et al., 2005; Sato
et al., 2003). In the current study, we have also provided the
first evidence that FEN1mRNA levels are linked to biologically
distinct integrative clusters reported in the METABRIC study
(Curtis et al., 2012). High FEN1 mRNA level was frequent in
intClust 10 subgroup which is the most highly genomically
instable subgroup with basal-like features. Interestingly, low
FEN1mRNA level was seen in intClust 3 subgroup that is char-
acterised by low genomic instability. Together the data pro-
vides evidence that high FEN1 mRNA could be utilised as a
biomarker of genomic instability in human tumours. In addi-
tion, high FEN1mRNA level is also frequently seen in intClust
5 (HER-2 enriched with worst survival), intClust 9 (8q cis-
acting/20qamplified mixed subgroup), and intClust 1 (17q23/
20q cis-acting luminal B subgroup) subgroups that also mani-
fest an aggressive phenotype. On the other hand, low FEN1
Figure 2 e FEN1 protein expression in breast cancer. (a) 1. Western blot showing specificity of FEN1 antibody. 2. Microphotographs of FEN1
protein expression in breast cancer tissue (magnification x200). Kaplan Meier curves showing breast cancer specific survival in the (b) ER negative
(L) breast cancer (whole cohort), (c) ER negative (L) breast cancer patients who received no chemotherapy. (d) ER negative (L) breast cancer
patients who received CMF chemotherapy, (e) ER positive (D) breast cancer patients (whole cohort), (f) high risk ER positive (D) breast cancer
patients who received no endocrine therapy and (g) high risk ER positive (D) breast cancer patients who received endocrine therapy. N[ nuclear
expression, C [ cytoplasmic expression, ‘L‘ [ negative expression, ‘D’ [ positive expression. (h).
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 3 2 6e1 3 3 8 1333mRNA level is linked to intClust 4 (includes both ER-positive
and ER-negative cases with a flat copy number landscape
and termed the ‘CNA-devoid’ subgroup with extensive lym-
phocytic infiltration), intClust 7 (16p gain/16q loss with higher
frequencies of 8q amplification luminal A subgroup) and
intClust 8 subgroups (classical 1q gain/16q loss luminal A sub-
group) (Curtis et al., 2012). The data implies differential roles
for FEN1 in distinct molecular phenotypes of breast cancer.
High FEN1mRNA is associatedwith poor survival in univariate
as well as in multivariate analyses in the whole cohort which
is likely to be related to the aggressive phenotype described
previously. As expected, intClust 10, intClust 9, intClust 5
and intClust 1 sub-groups that are associated with high
FEN1 levels were also associated with poor prognosis in
METABRIC study (Curtis et al., 2012). On the other hand,
intClust 3, intClust 4, intClust 7 and intClust 8 that areassociated with low FEN1 expression, are associated with
good to intermediate prognosis (Curtis et al., 2012). Together,
the data provides conclusive evidence that FEN1 mRNA level
has prognostic significance in breast cancer. To investigate if
FEN1mRNA expression may also have predictive significance,
we conducted sub-group analysis in tumours treated with
adjuvant chemotherapy or endocrine therapy. In patients
treated with endocrine therapy, we provide the first evidence
that high FEN1 mRNA level is associated with poor survival
implying resistance to endocrine therapy. The link between
FEN1, oestrogen and oestrogen receptors (ER) are beginning
to emerge. FEN1 not only interacts directly with ER-a but can
also augment the interaction of ER-awith oestrogen response
element containing DNA and impact upon estrogen-
responsive gene expression in cells (Buterin et al., 2006;
Moggs et al., 2005). Our data suggests that FEN1 mRNA over
Table 3 eMultivariate survival analysis using Cox regression for Nottingham breast cancer cohort.
Clinico-pathological variables ER negative cohort, breast cancer
specific survival at 10 years
ER negative cohort,
progression free
survival at 10 years
ER positive cohort,
breast cancer specific
survival at 10 years
ER positive cohort,
progression free
survival at 10 years
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
FEN1 protein expression 0.007* 0.003* 0.003* 0.004*
Nuc -/Cyt - 1 1 1 1
Nuc -/Cyt þ 1.314 (0.85e2.031) 1.617 (1.088e2.403) 1.53 (1.163e2.013) 1.75 (1.245e2.459)
Nuc þ /Cyt - 1.894 (1.239e2.896) 1.851 (1.254e2.731) 1.247 (0.828e1.883) 1.08 (0.605e1.929)
Nuc þ /Cyt þ 1.958 (1.194e3.213) 1.817 (1.130e2.920) 0.842 (0.551e1.287) 0.947 (0.543e1.653)
XRCC1 protein expression
(Continuous)
0.497 (0.347e0.713) <0.0001* 0.502 (0.36e0.701) <0.0001* 0.537 (0.384e0.753) <0.0001* 0.418 (0.282e0.619) <0.0001*
Tumour size (Continuous) 1.051 (1.011e1.092) 0.012* 1.042 (1.001e1.083) 0.43 1.101 (0.993e1.221) 0.069 1.052 (0.914e1.211) 0.480
Lymph node stage <0.0001* <0.0001* <0.0001* 0.001*
Negative 1 1 1 1
Positive (1e3 nodes) 1.13 (0.81e1.60) 1.157 (0.807e1.685) 1.666 (1.26e2.203) 1.848 (1.303e2.622)
Positive (>3 nodes) 2.23 (1.48e3.37) 5.286 (3.698e7.557) 3.346 (2.198e5.094) 4.331 (2.654e7.068)
Chemotherapy 0.029* 0.832 0.384 0.676
No 1 1 1 1
Yes 0.029 (0.64e0.976) 0.832 (0.687e1.007) 1.147 (0.842e1.562) 1.085 (0.739e1.594)
Tumour grade 0.477 0.821 0.07 <0.0001*
Grade 1(low) 1 1 1 1
Grade 2 (intermediate) 2.989 (0.379e23.579) 0.977 (0.282e3.382) 1.296 (0.903e1.86) 1.826 (1.036e3.22)
Grade 3 (high) 3.329 (0.451e24.603) 0.841 (0.26e2.723) 1.56 (1.064e2.288) 3.424 (1.952e6.008)
Lymphovascular invasion 0.705 0.635 0.033* 0.001*
No 1 1 1 1
Yes 0.941 (0.688e1.288) 1.073 (0.803e1.432) 1.324 (1.022e1.715) 1.71 (1.239e2.359)
Her2 expression (continuous) 1.107 (0.769e1.594) 0.585 1.061 (0.761e1.479) 0.726 1.229 (0.775e1.947) 0.381 1.549 (0.925e2.593) 0.096
* Statistically significant.
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Figure 3 e FEN1 protein expression in ovarian cancer. (a) Microphotographs of FEN1 protein expression in ovarian cancer tissue (magnification
x200). Investigating nuclear and cytoplasmic expression, Kaplan Meier curves showing cancer specific survival in epithelial ovarian cancer (b),
disease free survival (c). (d) Investigating nuclear expression of FEN1 alone, Kaplan Meier curves showing cancer specific survival. (e)
Investigating cytoplasmic expression of FEN1 alone, Kaplan Meier curves showing disease free survival (DFS) survival in epithelial ovarian cancer
patients.
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 3 2 6e1 3 3 8 1335expression is a novel biomarker for endocrine resistance and
is likely related to the role of FEN1 in cell proliferation. We
have also demonstrated for the first time that high FEN1
mRNA level is associated with poor survival in patients who
received adjuvant chemotherapy implying resistance to cyto-
toxic therapy.
We then investigated FEN1 protein expression immunohis-
tochemicaly in large cohorts of breast cancers. Althoughstrong association between FEN1 mRNA level and high
tumour grade as well as high mitotic index was evident,
FEN1 protein level analysis revealed a complex association
in breast cancer. In the ER positive cohort, grade 3 and higher
mitotic index tumours were more likely in low nuclear/high
cytoplasmic FEN1 tumours compared to high nuclear/low
cytoplasmic FEN1 or high nuclear/high cytoplasmic FEN1 tu-
mours. Surprisingly, grade 3 and high mitotic index tumours
MO L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 3 2 6e1 3 3 81336were also seen frequently in low nuclear/low cytoplasmic
FEN1 tumours in the ER positive cohort. In ER positive tumours
cytoplasmic over expression correlated to poor survival. In ER
negative tumours, although no significant clinicopathological
associations were seen, high nuclear FEN1 was associated
with poor survival. A limitation of our study is that it is retro-
spective and prospective studies will be needed to confirm our
observation. Given the complex multifunctional role of FEN1
protein that is likely regulated by sub-cellular compartmental-
ization and post-translational modification mechanisms, our
data suggest that detailed preclinical mechanistic studies
will be required to evaluate the roles of FEN1 protein in breast
cancer pathogenesis. However, it is important to note that the
clinical data presented here is consistent with a recent pre-
clinical study where FEN1 knockdown by siRNA was shown
to be associated with reduced cellular proliferation (van Pel
et al., 2013). Moreover, treatment with specific FEN1 inhibitors
isolated in that study also resulted in reduced proliferation in
cells (van Pel et al., 2013). In another preclinical study, FEN1
mRNA depletion by siRNA resulted in increased sensitivity
to chemotherapy such as alkylating agents and platinum
chemotherapy (Nikolova et al., 2009). Taken together the
data suggest that FEN1 mRNA levels are likely to be the best
predictors of response to chemotherapy or endocrine therapy
in breast cancer.
Interestingly, FEN1 protein expression also linked to other
DNA repair factors such as BRCA1, PARP1, XRCC1 and TOP2A
implying altered genomic stability in breast tumours. In
contrast to ER negative tumours, in ER positive tumours we
found an association between high FEN1 and ATM expression.
Previous studies indicate a functional link between FEN1 and
ER. FEN1 may regulate ER induced transcriptional response
by enhancing the interaction of ER with oestrogen response
elements- containing DNA (Schultz-Norton et al., 2007). Inter-
estingly a recent study suggests that ERmay be involved in the
regulation of ATM expression (Guo et al., 2013). In light of the
preclinical evidence presented above, the clinical data pre-
sented here suggest a complex network that may be operating
between ER, FEN1 and ATM in breast cancer cells. However,
detailed mechanistic studies are required to confirm this hy-
pothesis. In ovarian cancer, similarly, FEN1 expression is
linked to aggressive phenotype and poor survival. Recently,
we investigated FEN1 in gastric cancers (Abdel-Fatah et al.,
2013a). FEN1 protein over expression was associated with
high T-stage ( p ¼ 0.005), lymph node-positive disease
( p ¼ 0.02) and poor disease specific survival ( p ¼ 0.006)
(Abdel-Fatah et al., 2013a). In another study in prostate cancer,
FEN1 protein over expression was associated with aggressive
disease (Lam et al., 2006). Taken together the data suggest
that FEN1 protein expression has prognostic and predictive
significance in cancers.
Our clinical data suggests that FEN1 may be a promising
drug target in cancer. Interestingly, a recent study extrapo-
lating yeast genetic interaction data has also identified FEN1
as an attractive anti-cancer target (van Pel et al., 2013). We
have recently initiated a FEN1 drug discovery programme.
To facilitate the search for novel FEN1 inhibitors, we devel-
oped a fluorogenic donor/quencher reporter pair to monitor
generation of reaction product in real time (Dorjsuren et al.,
2011). A high-throughput screen was recently conducted on391,275 compounds arrayed as dilution series within a total
of 1407 plates. Primary screening data has been uploaded to
a public database (http://pubchem.ncbi.nlm.nih.gov/assay/
assay.cgi?aid¼588795). Detailed in vitro and in vivo evaluation
and validation of novel FEN1 inhibitors is an area of on-
going investigation in our laboratory.
In conclusion, the data presented in the current clinical
study suggests that FEN1 is promising biomarker in breast
and ovarian epithelial cancers.Conflict of interest
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